Viibryd (vilazodone hydrochloride) Patient Sheet
Viibryd Patient Counseling Information
Information for Patients
Advise patients and their caregivers about the benefits and risks associated with treatment with VIIBRYD and counsel them in its appropriate use. Advise patients and their caregivers to read the Medication Guide and assist them in understanding its contents. The complete text of the Medication Guide is reprinted at the end of this document.
Dosing and Administration
Instruct patients to take VIIBRYD with food. When initiating treatment with VIIBRYD the dose should be titrated, starting with a dose of 10 mg once daily for 7 days, followed by 20 mg once daily for an additional 7 days, and then increased to 40 mg once daily.
Instruct patients not to take VIIBRYD with an MAOI or within 14 days of stopping an MAOI and to allow 14 days after stopping VIIBRYD before starting an MAOI [see Contraindications].
Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like Reactions
Caution patients about the risk of serotonin syndrome or Neuroleptic Malignant Syndrome (NMS)-like reactions, particularly with the concomitant use of VIIBRYD and triptans, tramadol, tryptophan supplements, other serotonergic agents, or antipsychotic drugs [see Warnings and Precautions and Drug Interactions].
Caution patients about using VIIBRYD if they have a history of a seizure disorder [see Warnings and Precautions]. Patients with a history of seizures were excluded from clinical studies.
Caution patients about the concomitant use of VIIBRYD and NSAIDs, aspirin, warfarin, or other drugs that affect coagulation since combined use of psychotropic drugs that interfere with serotonin reuptake and these agents has been associated with an increased risk of abnormal bleeding [see Warnings and Precautions].
Activation of Mania/Hypomania
Advise patients and their caregivers to observe for signs of activation of mania/hypomania [see Warnings and Precautions].
Advise patients not to stop taking VIIBRYD without talking first with their healthcare provider. Patients should be aware that discontinuation effects may occur when suddenly stopping VIIBRYD [see Warnings and Precautions].
Advise patients that if they are treated with diuretics, or are otherwise volume depleted, or are elderly, they may be at greater risk of developing hyponatremia while taking VIIBRYD [see Warnings and Precautions].
Advise patients to avoid alcohol while taking VIIBRYD [see Drug Interactions].
Advise patients to notify their healthcare provider if they develop an allergic reaction such as rash, hives, swelling, or difficulty breathing.
Advise patients to notify their healthcare provider if they become pregnant or intend to become pregnant during therapy with VIIBRYD [see Use in Specific Populations].
Advise patients to notify their healthcare provider if they are breastfeeding an infant and would like to continue or start VIIBRYD [see Use in Specific Populations].
Interference with Cognitive and Motor Performance
Caution patients about operating hazardous machinery, including automobiles, until they are reasonably certain that VIIBRYD therapy does not adversely affect their ability to engage in such activities.
Trovis Pharmaceuticals LLC
New Haven, CT 06511
Licensed from Merck KGaA,
Product protected by U.S. Patent No. 5,532,241 and U.S. Patent No. 7,834,020.
VIIBRYD™ is a trademark of Trovis Pharmaceuticals LLC.
© 2011 Trovis Pharmaceuticals LLC.
Last update: January 2011
Writer, H. (2011, March 3). Viibryd (vilazodone hydrochloride) Patient Sheet, HealthyPlace. Retrieved on 2019, August 20 from https://www.healthyplace.com/other-info/psychiatric-medications/viibryd-vilazodone-hydrochloride-patient-sheet